Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews

This is a protocol for an overview of reviews to examine the diagnostic test accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of prostate cancers.

Date of publication: 20 Sep 2023
Authors: Andrew Dullea, Lydia O'Sullivan, Marie Carrigan, Susan Ahern, Maeve McGarry, Kirsty O'Brien, Patricia Harrington, Kieran A. Walsh, Susan M. Smith, Máirín Ryan
Journal: HRB Open Research
Digital object identifier: 10.12688/hrbopenres.13801.1
Type of output: Protocol
Suggested Citation:

Dullea A, O’Sullivan L, Carrigan M, Ahern S, McGarry M, O’Brien K, Harrington P, Walsh KA, Smith SM & Ryan M. Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews [version 1; peer review: 2 approved]. HRB Open Research. 2023;6. Available from: https://doi.org/10.12688/hrbopenres.13801.1

Generic justification

¹⁸F-prostate-specific membrane antigen (PSMA) PET/CT imaging for the staging of high-risk or recurrent prostate cancer: Evidence synthesis to support a generic justification decision

Published
Read publication